As part of the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, Jazz Pharmaceuticals participated in 16 new studies that will be shared at the meeting. In a press release, they highlighted particularly exciting studies related to their medications, such as Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) and Vyxeos® (daunorubicin and cytarabine), being used in treatments for patients with blood cancers.
The presentation about Rylaze is the first data being shared from a phase 2/3 study of the drug in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) (Abstract 2307). Rylaze is designed to treat patients after they develop a hypersensitivity or an allergy to a long-acting E. coli–derived asparaginase. The results being shared in this poster presentation indicate positive benefits for patients with ALL/LBL when using a Rylaze regimen.
Jazz also has 10 abstracts related to Vyxeos at ASH 2021. Of note, the company is part of an oral presentation taking place about an analysis of the real-world experience of clinicians and patients using Vyxeos as first-line treatment in patients with acute myeloid leukemia (AML) (Abstract 33). Additionally, there will be data shared about other real-world analytical studies focused on the treatment patterns of patients with therapy-related AML or AML-MRC (Abstract 1248) and treatment outcomes for patients with AML when using Vyxeos (Abstract 2310).
Dr. Robert Iannone, executive vice president, research and development, and chief medical officer of the company, reiterated Jazz Pharmaceuticals commitment to collaboration and making an impact for people with hematological disorders, as well as emphasizing how the data being presented at ASH 2021 related to the company’s medications illustrates that commitment .